Related Experiment Video

Updated: Jun 21, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

[Monoclonal antibodies and breast cancer. Current therapeutic progress]

J Collignon1, C Gennigens, A Rorive

  • 1Service d'Oncologie Médicale, CHU de Liège, Belgique.

Revue Medicale De Liege
|August 1, 2009
PubMed

Insights

Targeted therapies like trastuzumab and bevacizumab offer new breast cancer treatment options. These therapies target specific molecular events, improving outcomes for certain patient subgroups.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Breast cancer affects approximately 9,500 individuals in Belgium annually.
  • Advances in understanding tumor cell proliferation drivers have enabled targeted therapy development.
  • Trastuzumab and bevacizumab represent key targeted therapies in breast cancer treatment.

Purpose:

  • To review the benefits and roles of targeted therapies in breast cancer treatment.
  • To discuss the mechanism of action for trastuzumab and bevacizumab.
  • To highlight the significance of HER2 overexpression and VEGF inhibition.

Summary:

  • Trastuzumab, an anti-HER2 monoclonal antibody, is effective in breast cancers with human epidermal growth factor receptor type 2 (HER2) gene amplification, detected by fluorescence in situ hybridization (FISH).
  • Bevacizumab, an anti-VEGF monoclonal antibody, is another approved targeted therapy for breast cancer.
  • These targeted agents have demonstrated efficacy in both metastatic and adjuvant settings.

Impact:

  • Targeted therapies have revolutionized breast cancer treatment by addressing specific molecular alterations.
  • Improved patient outcomes are achievable through personalized treatment strategies based on molecular profiling.
  • The review underscores the evolving landscape of breast cancer therapeutics.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...